Lymphoma

Examining Progress and Future Directions in Follicular Lymphoma Treatment

Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.

Monjuvi Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

By

Brian Park, PharmD

Tafasitamab-cxix is a humanized Fc-modified monoclonal antibody that targets CD19 antigen on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including DLBCL.

Two Trials Evaluate CAR-T Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma

By

Vicki Moore, PhD

CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.

High Molecular Response With Lenalidomide, Rituximab in Untreated Follicular Lymphoma

By

Patricia Chaney

Researchers for the RELEVANCE study measured MRD in a subset of patients to compare the molecular response of patients receiving R2 vs R-chemo.

First CAR T-Cell Therapy Approved for Mantle Cell Lymphoma

By

Brian Park, PharmD

The FDA has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel; Kite Pharma) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

PET-Based Treatment Approach for Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

A prospective NCTN PET-directed analysis aimed to eradicate the short- and long-term toxicities associated with RT in patients with limited-stage DLBCL.

Allogeneic-HSCT Outcomes With Varied Donor Sources in Adult T-Cell Leukemia/Lymphoma

By

Vicki Moore, PhD

Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.

Real-World Data Confirm Early Efficacy of Axi-Cel in Refractory DLBCL

By

Andrea S. Blevins Primeau, PhD, MBA

A retrospective study found similar efficacy and toxicity outcomes among patients with refractory DLBCL who were treated with axi-cel outside of trial inclusion criteria.

Systematic Analysis Reveals Genomic Mutational Frequencies in MCL

By

Jonathan Goodman, MPhil

The authors noted that these findings should be seen as a reference for the mutational landscape in MCL at baseline and at disease progression after treatment.

Diagnosing and Managing Patients With Primary Pancreatic Lymphoma

By

Roxanne Nelson, RN, BSN

Because primary pancreatic lymphoma is a rare disease, optimal diagnostic and therapeutic protocols have not yet been established.

Selinexor in Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

A clinical trial suggests efficacy and a manageable adverse event profile with selinexor for the treatment of relapsed or refractory DLBCL.

Considerations for the Diagnostic Work-Up of Breast Implant–Associated Lymphoma

By

Andrea S. Blevins Primeau, PhD, MBA

Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.

T-Cell Lymphoblastic Lymphoma: Promising Results From Children’s Oncology Group AALL0434 Study

By

Jonathan Goodman, MPhil

AALL0434, one of the largest prospective studies of T-LL, resulted in successful disease-free and overall survival outcomes.

Addition of Rituximab to Chemotherapy for Pediatric High-Risk, Mature B-Cell NHL

By

Lauren Dembeck, PhD

For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.

Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

By

Brian Park, PharmD

The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

High-Intensity RIC-NMAC Regimen Associated With Greater Mortality Risk in Allogeneic Transplant NHL

By

Rita Aghjayan

High-intensity RIC-NMAC regimen Flu-Mel140, may be linked to higher nonrelapse mortality in patients with NHL undergoing allogeneic transplantation.

Tazverik Granted Accelerated Approval for Follicular Lymphoma

By

Brian Park, PharmD

Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

Response-Adapted Therapy May Benefit Patients With Early Extranodal Nasal-Type NK/T-Cell Lymphoma

By

Vicki Moore, PhD

Researchers conducted a multicenter, retrospective analysis of outcomes for 1360 patients who were treated with RT with or without nonanthracycline-based CT.

Risk-Adapted, Dose-Adjusted EPOCH-R Strategy in Previously Untreated Burkitt Lymphoma

By

Vicki Moore, PhD

Dose-adjusted EPOCH-R resulted in higher tolerance and efficacy among adults with Burkitt lymphoma.

Real-World Data Back Efficacy of Axi-Cel in R/R DLBCL

By

Leah Lawrence

Even among those with more comorbidities, safety, efficacy of treatment remained.

Oxaliplatin May Reduce Nephrotoxicity Compared With Cisplatin in B-Cell Lymphoma

By

Jonathan Goodman, MPhil

Researchers compared the efficacy and nephrotoxicity of R-DHAP vs R-DHAOx among patients treated for NHL between 2007 and 2014.

Evaluation of Primary Cardiac Lymphoma Incidence and Prognosis Using SEER Database

By

Dibash Kumar Das, PhD

SEER analysis reveals age, Ann Arbor stage, and chemotherapy as critical factors affecting prognosis in patients with primary cardiac lymphoma.

Nivolumab Is Promising as First-Line Treatment for Unfavorable Classic Hodgkin Lymphoma

By

Rita Aghjayan

Nivolumab-based first-line treatment may result in high remission and progression-free survival rates in early-stage unfavorable classic Hodgkin lymphoma.

Hypercalcemia as a Biomarker for Biological Aggressiveness of Diffuse Large B-Cell Lymphoma

By

Rita Aghjayan

Hypercalcemia is not uncommon in patients with de novo diffuse large B-cell lymphoma and may be linked to a higher risk for other adverse events.

Review of Features, Treatment Options in Peripheral T-Cell Lymphoma

By

Vicki Moore, PhD

Combined targeted agents with immune regulators and chimeric antigen receptor cell–based therapies may improve overall survival for patients with PTCL.

DNA Repair Gene-Related CHIP Is a Marker for Worse Outcomes in Patients With Lymphoma

By

Susan Moench

Clonal hematopoiesis of indeterminate origin has been defined as the presence of somatic mutations in hematopoietic stem cells at a variant gene frequency of more than 2%.

Requirements for Better Outcomes for Patients With Non-Hodgkin Lymphoma in Sub-Saharan Africa

By

Vicki Moore, PhD

Researchers oulined changes in diagnostics, surveillance, and treatment practices that could lead to better outcomes for patients with NHL in sub-Saharan Africa.

Dose-Adjusted EPOCH for B-Cell Lymphomas May Be Safe, Cost Effective in the Outpatient Setting

By

Lauren Dembeck, PhD

Researchers found that dose-adjusted (DA-) etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) for B-cell lymphomas can be administered safely in the outpatient setting and that outpatient administration was associated with significant savings relative to inpatient administration. Wenhui Li, PharmD, of the H. Lee Moffitt Cancer Center in Tampa, Florida, and colleagues published their findings in…

Age, Performance Status Linked With Failure to Complete R-CHOP in Diffuse Large B-Cell Lymphoma

By

Jonathan Goodman, MPhil

There is clinical and real-world evidence that indicates some patients do not complete treatment for reasons other than lack of response.

Molecular Determinants of Venetoclax Response in Acute Myeloid Leukemia Identified

By

Jonathan Goodman, MPhil

Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.

Copanlisib: Safe, Effective in Relapsed or Refractory B Cell Lymphoma

By

Jonathan Goodman, MPhil

Researchers conducted a 2-year safety and efficacy follow-up analysis to determine whether long-term data support the initial toxicity findings.

Lymphoid Malignancies: Novel Transplantations Are Improving Outcomes

By

Jonathan Goodman, MPhil

While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.

Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine

By

Vicki Moore, PhD

The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.

Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma

By

Vicki Moore, PhD

A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.

Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma

By

Vicki Moore, PhD

Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.

Elevated Risk for Cause-Specific Mortality in Waldenström Macroglobulinemia

By

Lauren Dembeck, PhD

Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.

Rituximab Failure Predicts Poor Outcome in DLBCL-Resembling Post-Transplant Lymphoproliferative Disorder

By

Jonathan Goodman, MPhil

Stable disease or progression compared with complete response was found to be predictive of overall survival in patients receiving rituximab-primary treatment.

Phase 1 Trial Outcomes With Urelumab in Relapsed or Refractory B-Cell Lymphoma

By

Vicki Moore, PhD

Half of responses with urelumab monotherapy were found to occur at a dosage above the maximum tolerated dose.

Clinical Response to Tisagenlecleucel Confers HRQoL Benefit in Lymphoma

By

Christina Bennett, MS

Patients with relapsed/refractory diffuse large B-cell lymphoma who responded to tisagenlecleucel also had improved health-related quality of life outcomes.

No Change in Transplant Outcomes for DLBCL With Addition of Rituximab to Conditioning

By

Abimbola Farinde, PharmD, PhD

Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.

Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma

By

Jonathan Goodman, MPhil

Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.

Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma

By

Susan Moench, PhD, PA-C

In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.

Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication

By

Brian Park, PharmD

The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.

Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma

By

John Schieszer, MA

Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.

Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL

By

Jonathan Goodman, MPhil

Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.

Brentuximab Vedotin May Improve Survival in Stage III/IV Classical Hodgkin Lymphoma

By

Lauren Dembeck, PhD

Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.

Current and Prospective Treatment Options for Waldenström Macroglobulinemia

By

Caleb Rans, PharmD

Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.

Pixantrone or Gemcitabine and Rituximab for Relapsed, Aggressive B-Cell Non-Hodgkin Lymphoma

By

Vicki Moore, PhD

Patients receiving pixantrone plus rituximab and patients receiving gemcitabine plus rituximab experienced similar progression-free survival.

Younger Age, Consolidation Therapy With Autologous SCT Associated With Improved OS in Patients With Primary CNS Lymphoma

By

Susan Moench, PhD, PA-C

Despite improvements in treatment of CNS lymphoma, median age of people who develop the disease is increasing. Nearly three-quarters of patients included in this population-based study were 60 years or older.

Deepened Responses in Waldenström Macroglobulinemia After Rituximab

By

Jonathan Goodman, MPhil

A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.

Bendamustine Improves Event-Free Survival in Elderly Patients With Indolent B-Cell Lymphomas

By

Jonathan Goodman, MPhil

Bendamustine-based first-line chemotherapy was associated with fewer hospitalizations and fewer toxic events compared with cyclophosphamide-based regimens.